Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21795445 | 0.88 | KDM4E (0.42) | TSHRALDH1A1BRD4KDM4EGAA | |
| SCHEMBL18419741 | 0.86 | JAK2 (0.49) | TSHRCYP1A2KMT2ABRD4AKR1C3 | |
| SCHEMBL5371884 | 0.83 | TSHR (0.53) | TSHRALDH1A1CYP1A2KMT2AAKR1C3 | |
| SCHEMBL22644496 | 0.83 | TSHR (0.53) | TSHRALDH1A1CYP1A2KMT2AAKR1C3 | |
| SCHEMBL16480067 | 0.80 | JAK2 (0.47) | ALDH1A1AKR1C3KDM4EALOX15POLB | |
| SCHEMBL18322797 | 0.78 | L3MBTL1 (0.35) | TSHRALDH1A1KDM4EGAAALOX15 | |
| SCHEMBL12522682 | 0.78 | TSHR (0.46) | TSHRALDH1A1CYP1A2KMT2AAKR1C3 | |
| SCHEMBL19028331 | 0.77 | MEN1 (0.44) | TSHRALDH1A1KMT2ABRD4AKR1C3 | |
| SCHEMBL12765364 | 0.77 | TSHR (0.41) | TSHRALDH1A1BRD4AKR1C3POLB | |
| SCHEMBL16477302 | 0.77 | JAK3 (0.45) | TSHRAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040162303-A1 | 4-aminopyrimidine-5-one derivatives | BARTKOVITZ DAVID JOSEPH (US) | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162303-A1 | 4-aminopyrimidine-5-one derivatives | CDK4, CDKL4, CDK6 | TSHR 4036/4885ALDH1A1 915/4885USP2 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.